Professor Lin Xin, Founder of Bristar Immunotech, Named to Elsevier's 'Highly Cited Chinese Researchers' List for Fourth Consecutive Year

This list uses Scopus, the globally authoritative citation and index database, as the statistical source for Chinese scholars' research achievements. It serves as an authoritative reference for identifying top scholars across various disciplines and research fields, systematically showcasing their breakthrough innovations in key technology research and critical areas. It is one of the key benchmarks for measuring scholars' academic influence. Professor Lin Xin's consecutive inclusion represents high recognition of his academic influence and demonstrates his team's leading position in the global research field.

Professor Lin Xin, as a renowned molecular immunologist, has been deeply engaged in T cell research for nearly 30 years, with academic achievements of significant international influence. In 2002, his important discovery was included in an authoritative English-language textbook. In 2014, Professor Lin returned to Tsinghua University, leading a team focused on translational research in T cell immunotherapy.Founded Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. in 2018, committed to translating cutting-edge scientific research achievements into innovative therapies that benefit patientsUnder his academic leadership, Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. has developed into an innovative cell therapy leader with a global perspective, and its technological breakthroughs and product advancements have drawn significant attention from the industry.

Professor Lin Xin's scientific research achievements are closely integrated with industrial practice. Relying on the research platform of Tsinghua University, Huaxia Yingtai (Beijing) Biotechnology Co., Ltd. has achieved original transformation.The STAR-T technology platform combines the dual advantages of antigen-antibody target recognition and natural TCR signaling, featuring high recognition sensitivity, strong tumor infiltration capability, and resistance to exhaustion., especially showing great potential in the fields of refractory tumors and autoimmune disease treatment. The STAR-T technology was globally published for the first time in a subsidiary journal of "Science" in 2021; with recent research expansion over the years, its advantages have gradually emerged, and new breakthrough progress of STAR-T was published in a subsidiary journal of "Cell" by the end of 2024.

In terms of product transformation, Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. has achieved fruitful results. Based on the STAR-T platform,The company has received two Class I new drug clinical trial approvals in China and one product has been granted "Orphan Drug" designation by the US FDA.。

In addition, the company actively promotes IIT research for multiple products under development and has made positive progress in clinical trials for solid tumors and autoimmune diseases. Among them, the GPC3 STAR-T study targeting advanced recurrent metastatic solid tumors, conducted in collaboration with Peking University Cancer Hospital and other institutions, has preliminarily demonstrated good clinical efficacy and gained high recognition from clinical researchers. Another allogeneic off-the-shelf product, CD19 STAR-T, developed using site-specific integration technology, has effectively controlled the conditions of several patients in exploratory clinical studies targeting severe systemic lupus erythematosus (SLE) and others, showcasing the clinical value of this innovative therapy.

Huaxia Yingtai's innovative practices have also gained widespread social recognition. As a representative enterprise in Beijing's "hard technology" sector, the company has attracted focused coverage from more than 30 authoritative mainstream media outlets and is regarded as a model for the transformation of Tsinghua University's scientific research achievements and top talent driving the development of the pharmaceuticals and health industry. Professor Lin Xin has repeatedly stated in interviews, "Transforming scientific research achievements into tools that benefit humanity is a common dream for scientists. In the future, our team will continue to drive breakthroughs in cell therapy technology through innovation, bringing more hope to patients worldwide."

With the continuous advancement of Huaxia Yingtai's technology research and product transformation, it will undoubtedly boost and lead the vigorous development of China's cell therapy industry, contributing Chinese strength to overcoming difficult-to-treat diseases such as cancer and autoimmune disorders.